A phase 3 trial of Cogent Biosciences’ bezuclastinib has hit its primary endpoint, teeing the biotech up to seek FDA approval ...

When Katie Doble was diagnosed with a rare cancer, she was given 16 months to live. Clinical trials gave her a second chance.

Results from all the trials used in the study were published between 2002 and 2024. The researchers identified 791 phase 3 clinical trials encompassing 555,580 patients for inclusion in the current ...

Taiho-developed TAS-205 is designed to selectively inhibit hematopoietic prostaglandin D synthase (HPGDS), an enzyme related ...

University of Wisconsin–Madison–led researchers report lower yet statistically non-significant recurrence of Clostridioides ...

A new study by investigators from Europe, including the Netherlands and the United Kingdom (UK), has shed light on ...

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the successful achievement of the primary endpoint ...

Results of two phase 2 studies suggest efgartigimod could be a potential treatment for myositis and Sjögren disease in ...

MR-141 Met Primary And All Secondary Endpoints, Demonstrating Rapid And Sustained Improvement In Near Visual Acuity Without Compromising Distance Vision Safety Profile ...

A new study by investigators from Europe, including the Netherlands and the United Kingdom (UK), has shed light on ...

Both regulatory-approved and pipeline treatments for moderate to severe hidradenitis suppurativa demonstrate comparable ...

A mixed bag of top-line phase II data prompted stellar stock results for Prokidney Corp. and its chronic kidney disease (CKD) and diabetes therapy, rilparencel. There were statistically significant ...